PTJ
RLAY icon

Paul Tudor Jones’s Relay Therapeutics RLAY Stock Holding History

Paul Tudor Jones’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-84,163
Closed -$712K – 4178
2025
Q4 		$712K Buy
84,163
+7,717
+10% +$55.1K ﹤0.01% 2505
2025
Q3 		$399K Buy
+76,446
New +$292K ﹤0.01% 2816
2025
Q2 		– Sell
-83,158
Closed -$218K – 3682
2025
Q1 		$218K Sell
83,158
-3,199
-4% -$12.5K ﹤0.01% 2815
2024
Q4 		$356K Buy
86,357
+5,674
+7% +$30.9K ﹤0.01% 2475
2024
Q3 		$571K Buy
80,683
+14,533
+22% +$109K ﹤0.01% 1951
2024
Q2 		$431K Buy
66,150
+709
+1% +$4.84K ﹤0.01% 1869
2024
Q1 		$543K Buy
65,441
+34,127
+109% +$333K ﹤0.01% 1619
2023
Q4 		$345K Sell
31,314
-24,679
-44% -$208K ﹤0.01% 1970
2023
Q3 		$471K Buy
+55,993
New +$602K ﹤0.01% 1705
2022
Q2 		– Sell
-33,922
Closed -$1.01M – 2460
2022
Q1 		$1.01M Buy
+33,922
New +$823K 0.02% 911
2021
Q1 		– Sell
-43,286
Closed -$1.8M – 1807
2020
Q4 		$1.8M Buy
43,286
+23,939
+124% +$1.08M 0.05% 455
2020
Q3 		$824K Buy
+19,347
New +$738K 0.04% 628

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Paul Tudor Jones's RLAY Position: Q1 2026 in Review

Paul Tudor Jones sold out of Relay Therapeutics (RLAY) in Q1 2026, closing a stake of 84,163 shares — an estimated $712K sold.

Paul Tudor Jones first reported a position in RLAY in Q3 2020 and held it in 12 quarters. The position peaked at $1.8M in Q4 2020. 243 funds tracked by Wall St. Rank hold RLAY as of Q1 2026.

  • Paul Tudor Jones reported no remaining Relay Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Paul Tudor Jones sold 84,163 Relay Therapeutics shares in Q1 2026, an estimated $712K.
  • Paul Tudor Jones first reported a position in Relay Therapeutics in Q3 2020 and held it in 12 quarters.
  • Paul Tudor Jones's Relay Therapeutics position peaked at $1.8M in Q4 2020.
  • 243 funds tracked by Wall St. Rank held Relay Therapeutics as of Q1 2026.

Based on Tudor Investment Corp's 13F filing for Q1 2026, filed 15 May 2026.